Clinical trials
catalyst calendar across sponsors →Studies where BIOA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 with posted results
Held by 12 tracked-famous managers (D. E. Shaw & Co., Inc., Balyasny Asset Management L.P., MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, +7 more) · FINRA short interest 1.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk FactorsNCT07656727Percent change in hsCRP (Dose A)Randomized · Double-masked · Treatment | Phase 2 | Recruiting | Drug: Oral BGE-102, Oral Placebo Matching BGE-102 | Obesity and Cardiovascular Risk | 160 | 2026-11-30 | in 102 d | 2026-06-18 |
| Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and OverNCT06515418Mean Percent Change in Body Weight (Azelaprag Once per Day)Randomized · Triple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Dosing of both study drugs has been discontinued due to observation of liver transaminitis without clinically significant symptoms in some subjects receiving azelaprag. All participant visits have been completed. | Drug: Oral Azelaprag (BGE-105), Oral Placebo for Azelaprag (BGE-105), Tirzepatide, Tirzepatide Placebo | Obesity | 204 | 2025-02-06actual | — | 2025-03-13 |
| Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy VolunteersNCT06141889Pharmacokinetics of azelaprag (BGE-105) after oral administration - AUC0-tRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Azelaprag | Healthy Volunteer Study | 16 | 2024-01-26actual | — | 2024-02-23 |
| Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip SurgeryNCT05152641Time to 2.0 g/dL Increase in Hemoglobin LevelRandomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: The program priority for execution of this clinical trial changed prior to enrollment of the first patient. The study was not withdrawn due to any safety concerns. | Drug: BGE-117, 4mg, BGE-117, 12mg · Dietary supplement: Ferrous Sulfate · Other: Matching Placebo | Acute Posthemorrhagic Anemia | 0 | Apr 2023 | — | 2022-05-05 |
| Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of AgingNCT04815603HemoglobinRandomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: The program priority for execution of this clinical trial changed prior to enrollment of the first patient. The study was not withdrawn due to any safety concerns. | Drug: BGE-117 · Other: Placebo | Anemia | 0 | Apr 2022 | — | 2022-05-05 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory FailureNCT04705597results2023-07-03Proportion of Participants Who Have Died or Progressed to Respiratory FailureRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The incidence of COVID-19 hospitalization cases decreased to a level that continued enrollment was no longer feasible | Drug: BGE-175 · Other: Placebo | Covid19 | 194 | 2022-04-20actual | — | 2023-07-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19